What initially stands out to me about Hims & Hers is the company's distinct branding and feel of luxury, which is evident on ...

Fintel reports that on January 10, 2025, Citigroup downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Neutral ...

Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst ...

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th.

NYSE:HIMS opened at $26.82 on Monday. The stock has a market cap of $5.86 billion, a price-to-earnings ratio of 60.96 and a beta of 1.31. The company’s 50 day moving average price is $26.73 and ...

In recent trading, shares of Hims & Hers Health Inc (Symbol: HIMS) have crossed above the average analyst 12-month target price of $25.36, changing hands for $26.63/share. When a stock reaches the ...

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...

Fintel reports that on January 7, 2025, BTIG initiated coverage of Hims & Hers Health (NYSE:HIMS) with a Buy recommendation.

Piper Sandler raised the firm’s price target on Hims & Hers to $24 from $21 and keeps a Neutral rating on the shares. Heading into the new year, the firm is watching the impact of rates and ...

Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $26.63 which represents a slight increase of $1.43 or 5.67% from the prior close of $25.2. The stock opened at $25.11 and ...

Hims offers convenient and affordable access to treatments and products tailored for men's health needs. But how much does it ...